WHAT DRIVES US
At Anticancer Bioscience, our work is fueled by curiosity, collaboration, and a commitment to meaningful impact. Every challenge we tackle inspires us to push scientific boundaries, explore innovative solutions, and support patients who need new hope. Behind each discovery is our dedicated team-scientists, clinicians, and innovators-turning bold ideas into therapies that can truly change lives.
MEET OUR TEAM
Anticancer Bioscience is a highly ambitious, emerging, fast-growing and international precision oncology company, led by a management team that has world-class expertise in cancer research, and in innovating genetic tools such as synthetic lethality and in the design of novel high-throughput screening approaches.
As well as access to the scientific expertise of the J. Michael Bishop Institute of Cancer Research, we are advised by leading scientists and clinicians in oncology.
Our commercial expertise is strengthened through the experience of our board
ACB MANAGEMENT TEAM
SCIENTIFIC ADVISORY BOARD
Dr. Dun Yang
Founder
Executive Chair
Chief Scientific Strategy Officer
PhD, Columbia University
Postdoc, University of California, San Francisco, mentored by Nobel Laureate Dr. J. Michael Bishop
Dr. J. Michael Bishop
Nobel Laureate in Physiology or Medicine in 1989
Member of the U.S. National Academy of Sciences
Member of the U.S. National Academy of Medicine
Foreign Member of the Royal Society, UK
Former Chancellor of the University of California, San Francisco
Chair of the Scientific and Medical Advisory Board at Anticancer Bioscience
Dr. Xudong Lu
Chief Executive Officer
PhD, Shanghai University of Finance and Economics
Over 20 years of experience in global capital markets and IPO execution
Dr. Hong Liu
Executive Vice President
Chief Medical Officer
PhD, University of California, Berkley
Postdoc, University of California, San Francisco, mentored by Nobel Laureate Dr. J. Michael Bishop
Dr. Jing Zhang
Co-founder
Senior Vice President, Clinical Development
PhD, University of Nottingham, UK.
Postdoc, University of St Andrews, UK
Dr. Robert Lloyd
Fellow of the Royal Society (UK)
Former Director, Institute of Genetics, University of Nottingham.
Synthetic Lethality Screening Specialist
Dr. Kevan Shokat
Member of the U.S. National Academy of Sciences
Member of the U.S. National Academy of Medicine
Foreign Member of the Royal Society, UK
Professor and Chair, Department of Cellular and Molecular Pharmacology in UCSF
Professor, Department of Chemistry in UC Berkeley
Investigator, Howard Hughes Medical Institute
Dr. Scott Kogan
Director of Hematopathology, University of California, San Francisco
Tenured Professor, Department of Laboratory Medicine,
UCSF School of Medicine and Helen Diller Family
Comprehensive Cancer Center
Dr. Dana Aftab
Executive Vice President and Chief Scientist, Exelixis
Dr. Dean Felsher
Director of Translational Research and Applied
Medicine, Department of Medicine, Stanford
University School of Medicine.
Co-Director Cancer Nanotechnology Program,
Department of Radiology, Stanford School of Medicine.
Director of Admissions/Associate Director,
Medical Scientist Training Program.
Dr. Frank Buchholz
Dean of Research at the Faculty of Medicine Carl
Gustav Carus, TU Dresden
Professor for Medical Systems Biology
Group Leader at the Max Planck Institute of
Molecular Cell Biology and Genetics